Fairvalue-Calculator Fairvalue-Calculator
EN DE

Prelude Therapeutics Incorporated (PRLD) Fair Value & Analysis

Healthcare · US · Market cap $344M

Price$4.38
Fair Value$4.76
Upside+8.7%
Quality95/100
Evidence: Low Range $3.57 – $5.95

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Prelude Therapeutics Incorporated (PRLD) currently trades at $4.38, while our model-based Fair Value estimate is $4.76 — implying the stock looks roughly 8.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Prelude Therapeutics Incorporated (PRLD) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $4.76 versus a price of $4.38 — about +9% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PRLD?
Our 21-model fair value for Prelude Therapeutics Incorporated is $4.76 (as of Jun 24, 2026), built from audited fundamentals. The current price is $4.38.
What is the quality score of PRLD?
Prelude Therapeutics Incorporated has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.